ERBB2 and breast carcinoma: A recent study of strategies to identify patients with breast cancer eligible for olaparib treatment reported that universal testing in patients with TNBC was cost-effective (ICER<$60 000 per QALY) compared with a selective testing strategy, and expanding testing to all patients with ERBB2-negative disease had a favorable ICER as well.33 Universal germline testing might have even greater value when cascade testing in family members is considered.